A study performed by Skoulidis F. et al. [41] showed that STK11/LKB1 co-mutations are associated with inferior objective response rate with PD-1 blockade in KRAS-mutant non-squamous NSCLC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.